Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05663320
Other study ID # 10000411
Secondary ID 000411-CC
Status Recruiting
Phase N/A
First received
Last updated
Start date June 26, 2024
Est. completion date December 1, 2025

Study information

Verified date October 3, 2023
Source National Institutes of Health Clinical Center (CC)
Contact Ruth W Parker, C.R.N.P.
Phone (301) 496-8533
Email ruth.parker@nih.gov
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Children with congenital adrenal hyperplasia (CAH) can survive well into adulthood with proper treatment. But the change from pediatric to adult care can be challenging. Many people with CAH need extra support as they learn to take control of their own health care needs. Researchers have studied how people respond to different types of patient education. Now researchers want to find out if virtual education, via computer, is a good way to teach people how to manage CAH as they become adults. Objective: To test a virtual method of delivering patient education to adolescents and young adults with CAH. Eligibility: Adolescents and young adults aged 16 to 22 years who have CAH. They must already be enrolled in Natural History Study Protocol 06-CH-0011. Design: Participants may take part in the study remotely; they may also come to the clinic. They will have 3 visits in 1 year. Participants will complete questionnaires. Topics will include what they know about CAH; whether they remember to take their medications on their own; and whether they schedule their own appointments. They will be asked about their quality of life. They will be asked about their physical and emotional health. All participants will be taught how to care for themselves. The participants will be divided into 2 groups. Some will watch an 11-minute video on CAH that focuses on their goals as they become adults. The others will receive standard education. After 6 months, participants will receive CAH education again. After 12 months, participants will repeat the questionnaires from their first visit.


Description:

Study Description: Health Care Transition (HCT) is defined as planned movement of chronically ill youth and young adults from a child to an adult model of care. HCT initiatives aim to facilitate the transition process and reduce commonly observed complications associated with poor transition such as decreased health literacy, poor treatment adherence, discontinuity of care and poor medical outcomes. The NIH Clinical Center is a unique environment where children with rare diseases such as Congenital Adrenal Hyperplasia (CAH) are often followed longitudinally into adulthood. Rare diseases are understudied and few studies have investigated effective ways of delivering HCT focused education to improve transition readiness. This is a pilot, randomized controlled trial that will assess the feasibility and preliminary efficacy of a virtual education-based transition intervention to improve transition readiness in adolescents and young adults with CAH. We hypothesize that the virtual education-based transition intervention will be feasible and participants in the intervention arm, will have better transition readiness score, disease outcomes and quality of life as compared to participants who received usual care. Objectives: Primary objective: To assess the feasibility of a virtual education based transition intervention in adolescents and young adults with CAH. Secondary Objective: To assess preliminary effectiveness of a virtual education-based transition intervention on measures of transition readiness. Endpoints: Primary Endpoint: a) study participant compliance rate of >= 67% with virtual education-based transition intervention, and b) feasibility of collecting all study questionnaires from >=75% of participants at all time periods. Secondary Endpoint: The change in baseline to 12 months in the University of North Carolina (UNC) Trxansition Index score.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date December 1, 2025
Est. primary completion date December 1, 2025
Accepts healthy volunteers No
Gender All
Age group 16 Years to 22 Years
Eligibility - INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: - Provision of signed and dated informed assent or consent form. - Stated willingness to comply with all study procedures and availability for the duration of the study. - Patients between ages 16-22 - Diagnosed with CAH and enrolled in the Natural History Study Protocol 06-CH-0011. - Ability to speak and comprehend English as this is a pilot study and the study intervention education video is currently only in English and requires validation before translation into other languages - Access to a computer/mobile device and the internet. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: - Patients with significant medical or cognitive impairment(s) that may interfere with participating in trial. - Participants unable to participate in all aspects of this clinical trial.

Study Design


Intervention

Other:
virtual educational based transition intervention self-paced
study intervention is a standardized, virtual educational video on CAH that will be delivered self-paced

Locations

Country Name City State
United States National Institutes of Health Clinical Center Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institutes of Health Clinical Center (CC)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary UNC Trxansition Index measure The UNC Trxansition Index is a validated, provider-administered transition readiness questionnaire. 12 months
Secondary Disease-specific knowledge Disease-specific knowledge 12 months
Secondary Self-Management and Transition to Adulthood with Rx (STARx) questionnaire Self-Management and Transition to Adulthood with Rx (STARx) questionnaire 12 months
Secondary Degree of disease control based on two commonly used adrenal biomarkers Degree of disease control based on two commonly used adrenal biomarkers 12 months
Secondary HRQoL based on Short Form Health Survey (SF-36). HRQoL based on Short Form Health Survey (SF-36). 12 months
Secondary Number of hospitalizations per year related to CAH Number of hospitalizations per year related to CAH 12 months
Secondary Number of school/work absences per year related to CAH Number of school/work absences per year related to CAH 12 months
See also
  Status Clinical Trial Phase
Completed NCT03687242 - Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia Phase 2
Active, not recruiting NCT04544410 - A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH Phase 2
Not yet recruiting NCT04087148 - Linear Growth of Children With Congenital Adrenal Hyperplasia
Completed NCT03162159 - Adult Height Prediction in Congenital Adrenal Hyperplasia
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Enrolling by invitation NCT05162950 - Effects and Importance of Epinephrine/Adrenalin Deficiency in CAH
Withdrawn NCT03532022 - Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy Phase 3
Recruiting NCT02795871 - Prenatal Dex Study N/A
Completed NCT02934399 - Dynamic Hormone Diagnostics in Endocrine Disease
Recruiting NCT04903587 - Gonadal Changes In Congenital Adrenal Hyperplasia Patients
Not yet recruiting NCT04536662 - Comparisons of Different Forms of Glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency Phase 4
Recruiting NCT04463316 - GROWing Up With Rare GENEtic Syndromes
Active, not recruiting NCT04490915 - Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia Phase 3
Completed NCT01807364 - Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia N/A
Completed NCT02804178 - A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia Phase 2
Completed NCT03019614 - An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone Phase 1
Not yet recruiting NCT04293133 - Final Height in Patients With CAH
Recruiting NCT03897504 - Surgical Evaluation of Using the Prepuce in Feminizing Genitoplasty N/A
Active, not recruiting NCT04806451 - Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study) Phase 3
Completed NCT01875640 - Decision Support for Parents Receiving Information About Child's Rare Disease